Alkermes plc. Revenue Recognition, Sales Returns, Reserve for Sales Returns
Alkermes plc. (ALKS) reported Revenue Recognition, Sales Returns, Reserve for Sales Returns of $13.50 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Notes
us-gaap:RevenueRecognitionSalesReturnsReserveForSalesReturns · last filed 2017-02-17
- Alkermes plc. revenue recognition, sales returns, reserve for sales returns for the quarter ending 2013-03-31 was $200.00K.
- Alkermes plc. revenue recognition, sales returns, reserve for sales returns for fiscal 2016 was $13.50M, a 101.49% increase from fiscal 2015.
- Alkermes plc. revenue recognition, sales returns, reserve for sales returns for fiscal 2015 was $6.70M, a 21.82% increase from fiscal 2014.
- Alkermes plc. revenue recognition, sales returns, reserve for sales returns for fiscal 2014 was $5.50M.
- Alkermes plc. revenue recognition, sales returns, reserve for sales returns for fiscal 2013 was $3.20M.
| Period end | Revenue Recognition, Sales Returns, Reserve for Sales Returns 3 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 9 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 12 month |
|---|---|---|---|
| 2016-12-31 | $13.50M 10-K · filed 2017-02-17 | ||
| 2015-12-31 | $6.70M 10-K · filed 2016-02-25 | ||
| 2014-12-31 | $5.50M 10-K · filed 2015-02-24 | ||
| 2013-12-31 | $3.80M 10-KT · filed 2014-02-27 | ||
| 2013-03-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $3.20M 10-K · filed 2013-05-23 | |
| 2012-12-31 | $3.00M 10-Q · filed 2013-01-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |